Santhera Pharmaceuticals Holding AG

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CH1276028821
CHF
12.20
-0.16 (-1.29%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROE of 15.77%

  • The company has been able to generate a Return on Equity (avg) of 15.77% signifying low profitability per unit of shareholders funds
2

High Debt Company with a Debt to Equity ratio (avg) at times

3

Poor long term growth as Net Sales has grown by an annual rate of -5.44% and Operating profit at -209.70% over the last 5 years

 
4

Negative results in Dec 24

5

Risky -

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CHF 171 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-21.94

stock-summary
Return on Equity

2,372.77%

stock-summary
Price to Book

-66.69

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-17.46%
0%
-17.46%
6 Months
-3.94%
0%
-3.94%
1 Year
27.35%
0%
27.35%
2 Years
16.86%
0%
16.86%
3 Years
125.93%
0%
125.93%
4 Years
-12.23%
0%
-12.23%
5 Years
-54.81%
0%
-54.81%

Santhera Pharmaceuticals Holding AG for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-5.44%
EBIT Growth (5y)
-209.70%
EBIT to Interest (avg)
-1.81
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.41
Sales to Capital Employed (avg)
0.66
Tax Ratio
0.75%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
18.51%
ROE (avg)
15.77%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-57.51
EV to EBIT
-3.99
EV to EBITDA
-4.49
EV to Capital Employed
3.79
EV to Sales
4.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-95.06%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Santhera Pharmaceuticals Holding AG"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 568.75% vs -110.67% in Dec 2021",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is -28.11% vs 18.02% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.50",
          "val2": "-1.60",
          "chgp": "568.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-42.20",
          "val2": "-53.40",
          "chgp": "20.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "20.20",
          "val2": "16.40",
          "chgp": "23.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.60",
          "val2": "5.20",
          "chgp": "-226.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-71.10",
          "val2": "-55.50",
          "chgp": "-28.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-6,137.70%",
          "val2": "0.00%",
          "chgp": "-613.77%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
7.50
-1.60
568.75%
Operating Profit (PBDIT) excl Other Income
-42.20
-53.40
20.97%
Interest
20.20
16.40
23.17%
Exceptional Items
-6.60
5.20
-226.92%
Consolidate Net Profit
-71.10
-55.50
-28.11%
Operating Profit Margin (Excl OI)
-6,137.70%
0.00%
-613.77%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2022 is 568.75% vs -110.67% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is -28.11% vs 18.02% in Dec 2021

stock-summaryCompany CV
About Santhera Pharmaceuticals Holding AG stock-summary
stock-summary
Santhera Pharmaceuticals Holding AG
Pharmaceuticals & Biotechnology
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone brands, which are primarily implemented in the symptomatic treatment of Leber's Hereditary Optic Neuropathy (LHON) diseases. Sathera Pharmaceuticals Holding AG operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Company Coordinates stock-summary
Company Details
Hohenrainstrasse 24 , PRATTELN None : 4133
stock-summary
Tel: 41 61 906895041 61 9068950
stock-summary
Registrar Details